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Initially, drugs were discovered by either chance or by trial and error through screening 
methods. Because scientists did not have the ability to model protein structures, drug 
discovery was a very expensive process. Currently, researchers are working on technologies 
to determine protein ligands and potential drugs through the usage of predicted protein 
structures.  
Docking for determining ligands experimentally models a protein structure 
without the presence of ligands. However, the Ligand-Steering Model 
(LSM) incorporates the structures of ligands into the predicted protein 
structure. Addition of ligands, to complete a protein structure, are modeled 
after preexisting proteins. Compared to other traditional methods of 
determining similarities, such as homology modeling, the LSM is shown to 
be more accurate in its protein prediction in its unliganded state. 
Docking for Determining Ligands1	
One method for structure-based drug design is docking. By using the structure of the 
protein’s activation site, a program can determine the ligand shape needed.  
Figure 1. Representation of how a docking program called DOCK 
determines the ligand. After determining the binding site, the program 
calculates spheres to associate with the binding site. Ligand atoms 
later replace the spheres.  
Characteristics of a Good Docking Program 
●  Takes in count of flexibility of the protein, ligand, and 
binding site 
●  has good scoring functions 
○  enables the docking program to quickly sort through 
ligand positions that do not work 
●  Fast virtual screening for large drug analyses  
●  The main difficulty in creating drugs for parasitic diseases is developing a drug that will 
target parasitic proteins without affecting host proteins. 
●  Protein structure prediction can help ease this issue. By determining structural 
differences between active enzymes in the parasite and host, researchers can create 
inhibitors that specifically target the parasite’s proteins. 
●  This idea has been implemented for targeting the dihydrofolate reductase-thymidylate 
synthase (DHFR-TS) enzyme which is present in 6 different types of parasites. (See 
Figure 4). 
Figure 4. In blue is the protein DHFR. In 
yellow is the ligand for the protein, and in 
red is the ligand created by a program 
called GOLD.  
Background Information:  
 
●  Over a third of all FDA-approved drugs target GPCRs.  
●  There are more than 800 GPCR genes expressed in 
humans 
●  Modeling GPCRs has been challenging through x-ray 
crystallography.  
○  only 16 unique class A GPCRs have been modeled 
so far  
 
Figure 2. Ligand and protein structures are combined in order 
to create a more accurate protein model. 
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                   Advances in Modeling 
 
●  Can now model complexes between small molecules and GCPRs if the transmembrane domain of 
the GPCR is mover 35% homologous to another GPCR.  
○  This means that researchers are able to model around 20% of nonolfactory class A GPCRs.  
●  Protein-ligand modeling has also been advancing.  
○  For example, the binding between the H4 receptor and its ligand has successfully been modeled.  
○  Modeling protein-ligand interactions can enable researchers to better understand the effects of 
ligand mutations. 
 
Figure 3. GPCR in its inactive and active 
states.  
“Biodetection of hCG Hormone,” (2012). iGEM. Retrieved from http://
2012.igem.org/Team:Chalmers-Gothenburg/Theory 
